Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | OTC | P00480 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.47 |
| ▸ | NOS2 | P35228 | 4/20 | 0.45 |
| ▸ | NOS3 | P29474 | 3/20 | 0.45 |
| ▸ | NOS1 | P29475 | 3/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | ARG1 | P05089 | 3/20 | 0.40 |
| ▸ | ARG2 | P78540 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL247131 | 1.00 | ALOX15 (0.50) | ALOX15OTCDDAH1NOS2NOS3 | |
| Arginine SCHEMBL27809411 | 1.00 | ALOX15 (0.50) | ALOX15OTCDDAH1NOS2NOS3 | |
| Arginine SCHEMBL28180160 | 0.98 | OTC (0.49) | ALOX15OTCDDAH1NOS2NOS3 | |
| Arginine SCHEMBL29020068 | 0.98 | OTC (0.49) | ALOX15OTCDDAH1NOS2NOS3 | |
| Arginine SCHEMBL6468371 | 0.95 | PMP22 (0.50) | ALOX15OTCDDAH1NOS2NOS3 | |
| Arginine SCHEMBL17874428 | 0.95 | PMP22 (0.50) | ALOX15OTCDDAH1NOS2NOS3 | |
| Arginine SCHEMBL17874429 | 0.95 | PMP22 (0.50) | ALOX15OTCDDAH1NOS2NOS3 | |
| Arginine SCHEMBL30883903 | 0.95 | OTC (0.49) | ALOX15OTCDDAH1NOS2NOS3 | |
| Arginine SCHEMBL6468370 | 0.95 | PMP22 (0.50) | ALOX15OTCDDAH1NOS2NOS3 | |
| Arginine SCHEMBL27776093 | 0.93 | OTC (0.50) | ALOX15OTCDDAH1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 557 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4640204-A2 | HAIR COSMETIC COMPOSITION | Kao Corporation (JP) | 2025-10-29 | — | — | EP | claimed |
| EP-3831362-B1 | HAIR COSMETIC COMPOSITION | KAO CORP (JP) | 2025-10-15 | — | — | EP | claimed |
| US-12350314-B2 | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | 89BIO, INC. (US) | 2025-07-08 | — | — | US | claimed |
| CN-119367551-A | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | 89生物公司 | 2025-01-28 | — | — | CN | claimed |
| US-20240307492-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | 89BIO, INC. (US) | 2024-09-19 | — | — | US | claimed |
| US-20240130956-A1 | HAIR COSMETIC COMPOSITION | KAO CORPORATION (JP) | 2024-04-25 | — | — | US | claimed |
| EP-4304625-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | 89Bio, Inc. (US) | 2024-01-17 | — | — | EP | claimed |
| US-11826448-B2 | Zinc-arginine-chloride complex | COLGATE-PALMOLIVE COMPANY (US) | 2023-11-28 | — | — | US | claimed |
| CN-117120070-A | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | 89生物公司 | 2023-11-24 | — | — | CN | claimed |
| US-20050020498-A1 | Apo-2 ligand/trail formulations | GENENTECH, INC. | 2005-01-27 | — | — | US | claimed |
| EP-1482894-A2 | COSMETIC FORMULATIONS CONTAINING L-ARGININE OLIGOMERS | Essentia Biosystems, Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-6797705-B2 | Rhamnan sulphate composition for treatment of endothelial dysfunction | ENDOMATRIX, INC. | 2004-09-28 | — | — | US | claimed |
| EP-1450847-A2 | APO2 LIGAND/TRAIL FORMULATIONS | GENENTECH, INC. (US) | 2004-09-01 | — | — | EP | claimed |
| US-20040116378-A1 | Novel composition and method for the treatment of diabetes | DANIELS, BRUCE A., M.D. | 2004-06-17 | — | — | US | claimed |
| US-20040067890-A1 | Ascorbic acid salts of organic bases with enhanced bioavailability for synergictic anti-aging and skin protective cosmetic compositions | GUPTA SHYAM K (US) | 2004-04-08 | — | — | US | claimed |
| WO-2003072039-A2 | COSMETIC FORMULATIONS CONTAINING L-ARGININE OLIGOMERS | ESSENTIA BIOSYSTEMS, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| WO-2003042344-A2 | APO2 LIGAND/TRAIL FORMULATIONS | GENENTECH, INC. (US) | 2003-05-22 | — | — | WO | claimed |
| EP-1238670-A1 | Composition and method for treating and preventing cardiovascular disease and hypertension. | Daniels, Bruce (US) | 2002-09-11 | — | — | EP | claimed |
| US-6255296-B1 | Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease | ENDOMATRIX, INC. | 2001-07-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240130956-A1 | HAIR COSMETIC COMPOSITION | PHOSPHO1, ODC1, H1-0 | ALOX15 1030/4885OTC 82/4885DDAH1 1296/4885 |
| US-12350314-B2 | Liquid formulations comprising mutant FGF-21 peptide pegylated conjugates | FGF1, FGFR1, FGF2 | ALOX15 1117/4885OTC 4121/4885DDAH1 3068/4885 |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | ALOX15 4155/4885OTC 3847/4885DDAH1 3015/4885 |
| US-20240307492-A1 | LIQUID FORMULATIONS COMPRISING MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES | FGF1, FGFR1, FGF2 | ALOX15 1117/4885OTC 4121/4885DDAH1 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.